Checkpoint Trends Ltd
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]
- Market Cap ₹ 22.8 Cr.
- Current Price ₹ 41.8
- High / Low ₹ 45.4 / 8.20
- Stock P/E 254
- Book Value ₹ 1.02
- Dividend Yield 0.00 %
- ROCE 16.5 %
- ROE 9.17 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 40.8 times its book value
- The company has delivered a poor sales growth of -12.8% over past five years.
- Company has a low return on equity of 0.00% over last 3 years.
- Company has high debtors of 212 days.
- Working capital days have increased from 220 days to 387 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.20 | 0.31 | 2.30 | 0.59 | 0.99 | 0.49 | 2.01 | 1.16 | 1.13 | 0.50 | 12.11 | |
0.06 | 0.07 | 0.21 | 0.28 | 2.33 | 0.77 | 0.97 | 0.48 | 2.03 | 1.24 | 1.10 | 0.40 | 12.00 | |
Operating Profit | -0.06 | -0.07 | -0.01 | 0.03 | -0.03 | -0.18 | 0.02 | 0.01 | -0.02 | -0.08 | 0.03 | 0.10 | 0.11 |
OPM % | -5.00% | 9.68% | -1.30% | -30.51% | 2.02% | 2.04% | -1.00% | -6.90% | 2.65% | 20.00% | 0.91% | ||
0.00 | -3.00 | 0.00 | 0.00 | -0.13 | 0.17 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | 0.00 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
Profit before tax | -0.06 | -3.07 | -0.01 | 0.03 | -0.16 | -0.01 | 0.05 | 0.01 | -0.02 | -0.08 | 0.02 | 0.05 | 0.11 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.00% | 0.00% | 50.00% | 0.00% | -50.00% | 40.00% | |
-0.06 | -3.07 | -0.01 | 0.03 | -0.16 | -0.01 | 0.03 | 0.01 | -0.04 | -0.08 | 0.03 | 0.03 | 0.09 | |
EPS in Rs | -0.11 | -5.61 | -0.02 | 0.05 | -0.29 | -0.02 | 0.05 | 0.02 | -0.07 | -0.15 | 0.05 | 0.05 | 0.16 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -13% |
3 Years: | -37% |
TTM: | 1076% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 38% |
3 Years: | 48% |
TTM: | -18% |
Stock Price CAGR | |
---|---|
10 Years: | 40% |
5 Years: | 82% |
3 Years: | 140% |
1 Year: | 375% |
Return on Equity | |
---|---|
10 Years: | -1% |
5 Years: | -1% |
3 Years: | 0% |
Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 |
Reserves | -2.00 | -5.08 | -5.08 | -5.05 | -4.87 | -4.89 | -4.85 | -4.85 | -4.88 | -4.96 | -4.94 | -4.91 |
0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 | 0.00 | 0.00 | |
0.08 | 0.07 | 0.06 | 0.11 | 0.21 | 0.12 | 0.13 | 0.29 | 0.26 | 0.00 | 0.40 | 0.09 | |
Total Liabilities | 3.78 | 0.46 | 0.45 | 0.53 | 0.81 | 0.70 | 0.75 | 0.91 | 0.85 | 0.66 | 0.93 | 0.65 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.06 | 0.07 | 0.00 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
3.78 | 0.46 | 0.45 | 0.53 | 0.81 | 0.68 | 0.73 | 0.90 | 0.84 | 0.60 | 0.86 | 0.65 | |
Total Assets | 3.78 | 0.46 | 0.45 | 0.53 | 0.81 | 0.70 | 0.75 | 0.91 | 0.85 | 0.66 | 0.93 | 0.65 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -0.08 | -0.01 | 0.04 | 0.18 | -0.03 | 0.12 | 0.52 | -0.50 | 0.01 | -0.02 | 0.19 | |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.18 | |
0.06 | -0.23 | -0.02 | 0.02 | 0.00 | -0.17 | -0.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | 0.01 | -0.31 | -0.03 | 0.06 | 0.18 | -0.20 | -0.14 | 0.52 | -0.50 | 0.01 | -0.02 | 0.01 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 36.50 | 23.55 | 53.96 | 179.41 | 106.92 | 163.88 | 121.67 | 135.30 | 229.34 | 211.70 | ||
Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Days Payable | ||||||||||||
Cash Conversion Cycle | 36.50 | 23.55 | 53.96 | 179.41 | 106.92 | 163.88 | 121.67 | 135.30 | 229.34 | 211.70 | ||
Working Capital Days | 18.25 | -35.32 | 36.50 | 259.83 | 221.21 | 59.59 | 98.06 | 129.01 | 145.35 | 386.90 | ||
ROCE % | -1.62% | -3.42% | -2.56% | 7.41% | 25.49% | -30.51% | 3.33% | 1.61% | -3.31% | -12.80% | 3.36% | 16.51% |
Documents
Announcements
-
Board Meeting Outcome for Issuance Of Warrants And QIB
1d - Board approved up to Rs500 crore QIP and 51,436,781 preferential convertible warrants; EGM on October 13, 2025, for approvals.
-
Newspaper Advertisement
4 Sep - Checkpoint Trends published AGM notice in Business Standard and Mumbai Lakshadeep on Sep 3, 2025 (Scrip 531099).
-
Reg. 34 (1) Annual Report.
2 Sep - Annual report filed; FY25 profit Rs2.54 lakh; authorized capital raised to Rs75 crore; proposed Rs300 crore; AGM Sept 29, 2025.
-
Notice Of AGM
2 Sep - AGM on September 29, 2025; adopt FY2024-25 accounts; appoint DSM & Associates as secretarial auditor (2025-26 to 2029-30).
-
Board Meeting Intimation for Board Meeting Intimation For Raising Of Funds
1 Sep - Board meeting Sept 10, 2025 to consider preferential allotment/convertible warrants/QIP fundraising; books shifted to Nashik.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
CTL (Formerly Rubra Medicaments Ltd) was engaged in the manufacture and sale of pharmaceutical formulations based in Hyderabad. The company is currently in the business of trading and providing different kinds of consulting services in India to all categories of clients.